Does Enrollment in Cancer Trials Improve Survival?
- 1 April 2013
- journal article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 216 (4) , 774-780
Abstract
Stakeholders derive many benefits from cancer clinical trials, including guidance for future oncologic treatment decisions. However, whether enrollment in cancer trials also improves patient survival independently of trial outcomes remains underinvestigated. We hypothesized that cancer trial enrollment is not associated with patient survival outcomes. Using the 2002 to 2008 California Cancer Registry, we identified 555,469 patients with stage I to IV solid organ tumors. Baseline characteristics were compared by trial participation status. Logistic regression determined predictors of trial enrollment. Multivariate Cox proportional hazards regression examined the impact of trial participation on overall and cancer-specific mortality with adjustment for covariates. Only 0.33% of our cohort was enrolled in clinical trials. Trial participants were likely to be younger than 65 (odds ratio [OR] 2.13; 95% CI 1.90 to 2.38), Hispanic rather than non-Hispanic white (OR 0.78; 95% CI 0.67 to 0.90), and have breast cancer (OR 3.14; 95% CI 2.62 to 3.77). Multivariate survival analyses demonstrated that enrollment in cancer trials predicted a lower hazard of death. However, when stratified by disease site, this survival benefit was observed only in lung, colon, and breast cancers. Sensitivity and interaction analyses confirmed these relationships. In this first population-based study examining trial effect in solid organ cancers, enrollment into cancer trials predicted lower overall and cancer-specific mortality among common cancer sites. Although these findings may demonstrate a survival benefit due to trial enrollment, they likely also reflect the favorable attributes of trial enrollees. Once corroborated, stakeholders must consider broader cancer trial designs representative of the cancer burden treated in the real world.Keywords
This publication has 25 references indexed in Scilit:
- Population–Based Evaluation of Adenosquamous Carcinoma of the Colon and RectumDiseases of the Colon & Rectum, 2012
- Clinical Trial Participation and Time to Treatment Among Adolescents and Young Adults With Cancer: Does Age at Diagnosis or Insurance Make a Difference?Journal of Clinical Oncology, 2011
- Extremity Soft Tissue Sarcoma Care in the Elderly: Insights into the Generalizability of NCI Cancer TrialsAnnals of Surgical Oncology, 2010
- Insurance Status, Comorbidity Level, and Survival Among Colorectal Cancer Patients Age 18 to 64 Years in the National Cancer Data Base From 2003 to 2005Journal of Clinical Oncology, 2009
- Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic reviewCancer, 2007
- Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based DisparitiesAnnals of Surgical Oncology, 2007
- Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988–2000Cancer, 2006
- Generalizability of cancer clinical trial resultsCancer, 2006
- External validity of randomised controlled trials: “To whom do the results of this trial apply?”The Lancet, 2005
- Improved Survival and Reduction in Local Failure Rates After Preoperative RadiotherapyAnnals of Surgery, 1999